DRIVE-FORWARD and DRIVE-AHEAD: Safety and Efficacy of Doravirine in Treatment-Naive Adults at 4 Yr

October 27-30, 2021; London, United Kingdom
In combined analysis of open-label extension, maintenance of virologic suppression was demonstrated through 192 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 185 KB
Released: November 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Commentary from Dr Karine Lacombe on the potential role of an investigational 2-drug regimen of lenacapavir plus islatravir, from Clinical Care Options (CCO)

Karine Lacombe, MD, PhD Released: November 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue